These findings highlight the critical importance of early genetic diagnosis and the timely initiation of deoxynucleoside therapy, which can improve respiratory muscle function and significantly extend the survival of MDS patients associated with TK2 mutations. This evidence concerns the gene TK2 and myelodysplastic syndrome.